Exelixis
@ExelixisInc
Followers
6K
Following
65
Media
1K
Statuses
1K
Biotechnology company striving to accelerate the development of new medicines for difficult-to-treat cancers. See our guidelines: https://t.co/bjFwsNq1eQ
Alameda, CA
Joined October 2010
ATTN Investors: $EXEL Q2 earnings announcement details available here:
0
1
1
NEWS: Our partner Ipsen received European Commission approval of $EXEL flagship therapy for patients with previously treated advanced #NeuroendocrineTumors (NET). Learn more:
0
2
6
Positive findings announced from a phase 3 pivotal trial of $EXEL third-generation TKI in combination with an immunotherapy in patients with metastatic #ColorectalCancer. Details available here:
0
1
4
Just announced: Our partner Ipsen received a positive CHMP opinion in the EU for $EXEL flagship therapy for patients with previously treated advanced #NeuroendocrineTumors. Learn more:
0
1
7
See results from an expansion cohort of the phase 1b/2 study of our third-generation TKI in combination with immune checkpoint inhibitors in advanced #KidneyCancer at #ASCO25. Data from multiple dose-finding cohorts will also be presented: $EXEL
0
2
2
Dusty finds strength through family connection, self-advocacy and learning as much as she can following her diagnosis of #NeuroendocrineTumors (NET). Watch as Dusty shares her experiences and the many sources of hope in her life.
0
2
1
ATTN Investors: $EXEL Q1’25 earnings announcement details available here:
0
1
2
ATTN $EXEL Investors: Q1’25 earnings webcast coming soon. Details:
0
1
2
We appreciated the opportunity to support this year's @AACRFoundation Scientist <-> Survivor program, which fosters relationships between scientific and advocacy community leaders. #AACR25.
The @AACR Scientist↔Survivor Program® creates enduring partnerships among cancer survivors, advocates, and scientists. By strengthening collaboration, #AACRSSP helps improve clinical trial design and enhance access to cancer information. Learn more:
0
2
3
See our 2024 Annual Report to learn how the growth of our flagship therapy is further fueling a new generation of our medicines: $EXEL
1
0
1
NEWS: We are excited to announce that the U.S. Food and Drug Administration has approved $EXEL flagship therapy for the treatment of previously treated advanced #NeuroendocrineTumors (NET). Details here:
3
5
12
Preclinical data from four $EXEL pipeline molecules to be presented for the first time at #AACR25. Read more:
0
1
2
Final 5-year results from trial of $EXEL flagship product in combination with @BMSnews immunotherapy for patients with advanced #KidneyCancer presented at #GU25. Read more:
0
1
3
ATTN Investors: $EXEL Q4 and Full Year 2024 earnings announcement details available here:
0
1
2
ATTN $EXEL Investors: Q4 and Full Year 2024 earnings webcast coming soon. Details:
0
1
0
See results from the phase 1b/2 study of $EXEL third-generation TKI in combination with an immune checkpoint inhibitor in patients with metastatic #ColorectalCancer at #GI25. Read more:
0
1
6